Status In progress
Process STA
ID number 1041

Provisional Schedule

Appraisal consultation: 1 01 February 2018 - 01 March 2018
Committee meeting: 2 14 March 2018
Expected publication 20 June 2018

Project Team

Project lead Thomas Feist

Email enquiries

Consultees

Companies sponsors Niraparib (TESARO)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Royal College of Obstetricians & Gynaecologists
  British Gynaecological Cancer Society
  Ovacome
  Ovarian Cancer Action
  Target Ovarian Cancer

Commentators

Comparator companies Merck Sharp and Dohme
General commentators Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland

Timeline

Key events during the development of the guidance:

Date Update
16 January 2018 Committee meeting: 1
18 October 2017 The appraisal of Niraparib for people who have recurrent, platinum-sensitive ovarian, fallopian tube or peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy has been rescheduled to allow the company to provide further data, requested by NICE and the Evidence Review Group, to inform their submission. The first committee meeting will now take place on 16 January 2017.
07 July 2017 Invitation to participate
19 May 2017 Following on from advice received from the company this appraisal has been rescheduled. Therefore, we now anticipate that the appraisal will begin during early July 2017 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early September 2017.
22 July 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance